Table 1 Patient characteristics (n = 42) stratified by nodal status
Total patients (n = 42) | No LN metastases (n = 27) | LN metastases (n = 15) | P value | |
|---|---|---|---|---|
Age, year, mean, median (range) | 68.86, 69 (55–82) | 69.26, 69 (55–82) | 70.93, 74 (55–79) | 0.503 |
PSA, ng/ml, mean, median (range) | 52.31, 37.25 (7.20–348.00) | 37.14, 23.50 (7.20–128.40) | 79.63, 54.30 (10.95–348.00) | 0.029 |
Gleason score at RP (%) | 0.028 | |||
3 + 4 | 9 (21.43) | 9 (33.33) | 0 (0) | |
4 + 3 | 9 (21.43) | 6 (22.22) | 3 (20.00) | |
≥ 4 + 4 | 24 (57.14) | 12 (44.44) | 12 (80.00) | |
pT stage at RP, no. (%) | 0.004 | |||
pT2 | 11 (26.19) | 11 (40.74) | 0 (0) | |
pT3a | 8 (19.05) | 6 (22.22) | 2 (13.33) | |
pT3b | 23 (54.76) | 10 (37.04) | 13 (86.67) | |
Intraprostatic PCa size, cm, mean, median (range) | 2.72, 2.55 (0.70–5.30) | 2.43, 2.30 (0.70–4.30) | 3.24, 3.2 (1.00–5.30) | 0.828 |
Intraprostatic PCa volume, ml, mean, median (range) | 10.04, 5.46 (0.13–49.00) | 6.84, 4.33 (0.126–31.046) | 15.86, 9.46 (0.32–48.99) | 0.008 |
LNs removed, no. (%) | 621 (100) | 381 (61.35) | 240 (38.65) | – |
LNMs removed, no. (%) | 51 (100) | – | 51 (100) | – |
Short-axis diameter < 5 mm | 0 | – | 0 | – |
Short axis diameter 5–10 mm | 9 | – | 9 | – |
Short-axis diameter > 10 mm | 42 | – | 42 | – |
Intranodal LNM size, mma, mean, median (range) | 14.67, 13.00 (7–31) | – | 14.67, 13.00 (7–31) | – |
Overall LNM size, mma, mean, median (range) | 28.87, 30.00 (16–45) | – | 28.87, 30.00 (16–45) | – |
SUV, maximal LN, mean, median (range) | 7.35, 5.40 (4.5–27.72) | – | 7.35, 5.40 (4.5–27.72) | – |
SUV, maximum PCa, mean, median (range) | 9.32, 7.60 (5.4–51.75) | 7.22, 6.7 (5.4–11.2) | 13.10, 8.12 (6.12–51.75) | < 0.001 |